HHLR Advisors’s Allogene Therapeutics ALLO Stock Holding History

HHLR Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-623,434	Closed	-$3.92M	–	71
2022 Q4	$3.92M	Sell	623,434 -176,566	-22%	-$1.63M	0.08%	50
2022 Q3	$8.64M	Hold	800,000	–	–	0.23%	37
2022 Q2	$9.12M	Hold	800,000	–	–	0.2%	35
2022 Q1	$7.29M	Hold	800,000	–	–	0.15%	38
2021 Q4	$11.9M	Hold	800,000	–	–	0.18%	44
2021 Q3	$20.6M	Hold	800,000	–	–	0.27%	43
2021 Q2	$20.9M	Hold	800,000	–	–	0.21%	52
2021 Q1	$28.2M	Hold	800,000	–	–	0.28%	40
2020 Q4	$20.2M	Hold	800,000	–	–	0.16%	58
2020 Q3	$30.2M	Hold	800,000	–	–	0.23%	37
2020 Q2	$34.3M	Buy	+800,000	New	+$28.9M	0.31%	32

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HHLR Advisors's ALLO Position: Q1 2023 in Review

HHLR Advisors sold out of Allogene Therapeutics (ALLO) in Q1 2023, closing a stake of 623,434 shares — an estimated $3.92M sold.

HHLR Advisors first reported a position in ALLO in Q2 2020 and held it in 11 quarters. The position peaked at $34.3M in Q2 2020. 176 funds tracked by Wall St. Rank hold ALLO as of Q1 2023.

HHLR Advisors reported no remaining Allogene Therapeutics position as of Q1 2023 after selling out during the quarter.
HHLR Advisors sold 623,434 Allogene Therapeutics shares in Q1 2023, an estimated $3.92M.
HHLR Advisors first reported a position in Allogene Therapeutics in Q2 2020 and held it in 11 quarters.
HHLR Advisors's Allogene Therapeutics position peaked at $34.3M in Q2 2020.
176 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2023.

Based on HHLR Advisors's 13F filing for Q1 2023, filed 15 May 2023.